SCHEMBL996955

SCHEMBL996955

CC(C)(C)OC(=O)NC[C@H](C(=O)O)N1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 1/20 0.44
CHRM2 P08172 2/20 0.40
CHRM4 P08173 2/20 0.40
CHRM5 P08912 2/20 0.40
CHRM1 P11229 2/20 0.40
CHRM3 P20309 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
EPHX1 P07099 1/20 0.40
CTSL P07711 2/20 0.39
ACHE P22303 1/20 0.38
BACE1 P56817 1/20 0.38
CTSK P43235 4/20 0.37
CTSB P07858 1/20 0.37
CTSS P25774 2/20 0.37
SYK P43405 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
SERPINE1 P05121 1/20 0.36
CNR2 P34972 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL996956 1.00 MEN1 (0.44) MEN1GAAKMT2ACHRM2CHRM4
SCHEMBL997414 1.00 MEN1 (0.44) MEN1GAAKMT2ACHRM2CHRM4
SCHEMBL997131 0.98 MEN1 (0.45) MEN1GAAKMT2ACHRM2CHRM4
SCHEMBL997132 0.98 MEN1 (0.45) MEN1GAAKMT2ACHRM2CHRM4
SCHEMBL1503589 0.87 L3MBTL1 (0.39) MEN1GAAKMT2AL3MBTL1EPHX1
SCHEMBL10079851 0.87 L3MBTL1 (0.39) MEN1GAAKMT2AL3MBTL1EPHX1
SCHEMBL995076 0.86 MEN1 (0.42) MEN1GAAKMT2ACHRM2CHRM4
SCHEMBL996282 0.86 MEN1 (0.42) MEN1GAAKMT2AL3MBTL1CTSL
SCHEMBL995075 0.86 MEN1 (0.42) MEN1GAAKMT2ACHRM2CHRM4
SCHEMBL996283 0.86 MEN1 (0.42) MEN1GAAKMT2AL3MBTL1CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2448931-B1 Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine GALDERMA RES & DEV (FR) 2015-05-27 EP disclosed
US-8772478-B2 Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2014-07-08 US disclosed
US-20120116072-A1 NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS GALDERMA RESEARCH & DEVELOPEMENT (FR) 2012-05-10 US disclosed
EP-2448931-A1 NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS Galderma Research & Development (FR) 2012-05-09 EP disclosed
WO-2011001088-A1 NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120116072-A1 NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS TYR, ARSA, STS MEN1 2269/4885GAA 276/4885KMT2A 1788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.